Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K6 | O95382 | 3/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984680 | 0.92 | MAP3K6 (0.34) | MAP3K6MAP3K5BTKRIPK2MDM4 | |
| SCHEMBL981754 | 0.89 | MCHR1 (0.37) | BTKRIPK2PAK1CD38IRAK4 | |
| SCHEMBL981807 | 0.88 | MDM4 (0.38) | MAP3K6MAP3K5BTKMDM4PAK1 | |
| SCHEMBL985732 | 0.87 | KDR (0.37) | MAP3K6MAP3K5BTKCD38IRAK4 | |
| SCHEMBL986300 | 0.87 | CDK9 (0.39) | MAP3K6MAP3K5MDM4CD38IRAK4 | |
| SCHEMBL984278 | 0.86 | MAP3K5 (0.37) | MAP3K6MAP3K5BTKMDM4HPGDS | |
| SCHEMBL982064 | 0.86 | MAP3K5 (0.37) | MAP3K6MAP3K5BTKMDM4HPGDS | |
| SCHEMBL982969 | 0.86 | BRD4 (0.39) | CD38IRAK4 | |
| SCHEMBL984600 | 0.86 | BTK (0.40) | BTKMDM4PAK1CD38IRAK4 | |
| SCHEMBL984887 | 0.85 | HPGDS (0.44) | MDM4PAK1CD38IRAK4HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | MAP3K6 2724/4885MAP3K5 1564/4885BTK 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.